Tango Therapeutics Inc (TNGX) - Net Assets
Based on the latest financial reports, Tango Therapeutics Inc (TNGX) has net assets worth $346.18 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($398.69 Million) and total liabilities ($52.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore cash efficiency ratio of Tango Therapeutics Inc to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $346.18 Million |
| % of Total Assets | 86.83% |
| Annual Growth Rate | 87.72% |
| 5-Year Change | 0.42% |
| 10-Year Change | N/A |
| Growth Volatility | 300.94 |
Tango Therapeutics Inc - Net Assets Trend (2019–2025)
This chart illustrates how Tango Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Tango Therapeutics Inc assets under control for the complete picture of this company's asset base.
Annual Net Assets for Tango Therapeutics Inc (2019–2025)
The table below shows the annual net assets of Tango Therapeutics Inc from 2019 to 2025. For live valuation and market cap data, see Tango Therapeutics Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $346.18 Million | +73.51% |
| 2024-12-31 | $199.52 Million | -21.17% |
| 2023-12-31 | $253.11 Million | +1.46% |
| 2022-12-31 | $249.48 Million | -27.64% |
| 2021-12-31 | $344.75 Million | +793.13% |
| 2020-12-31 | $38.60 Million | +388.30% |
| 2019-12-31 | $7.91 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tango Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 55202300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $136.00K | 0.04% |
| Other Comprehensive Income | $224.00K | 0.06% |
| Other Components | $948.97 Million | 274.13% |
| Total Equity | $346.18 Million | 100.00% |
Tango Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Tango Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Holitech Technology Co Ltd
SHE:002217
|
$2.83 Billion |
|
Sinochem International Corp
SHG:600500
|
$2.84 Billion |
|
Altarea SCA
PA:ALTA
|
$2.84 Billion |
|
Wihlborgs Fastigheter AB
ST:WIHL
|
$2.84 Billion |
|
SIMMTECH Co. Ltd
KQ:222800
|
$2.83 Billion |
|
IRB Infrastructure Developers Limited
NSE:IRB
|
$2.83 Billion |
|
NH Hoteles
MC:NHH
|
$2.83 Billion |
|
Madison Square Garden Entertainment Corp
NYSE:MSGE
|
$2.83 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tango Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 199,517,000 to 346,179,000, a change of 146,662,000 (73.5%).
- Net loss of 101,594,000 reduced equity.
- New share issuances of 212,400,000 increased equity.
- Other comprehensive income decreased equity by 112,000.
- Other factors increased equity by 35,968,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-101.59 Million | -29.35% |
| Share Issuances | $212.40 Million | +61.36% |
| Other Comprehensive Income | $-112.00K | -0.03% |
| Other Changes | $35.97 Million | +10.39% |
| Total Change | $- | 73.51% |
Book Value vs Market Value Analysis
This analysis compares Tango Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.59x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 217.44x to 6.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.09 | $19.65 | x |
| 2020-12-31 | $0.44 | $19.65 | x |
| 2021-12-31 | $5.55 | $19.65 | x |
| 2022-12-31 | $2.84 | $19.65 | x |
| 2023-12-31 | $2.68 | $19.65 | x |
| 2024-12-31 | $1.83 | $19.65 | x |
| 2025-12-31 | $2.98 | $19.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tango Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -162.85%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.15x
- Recent ROE (-29.35%) is above the historical average (-72.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -178.30% | -57.18% | 0.44x | 7.05x | $-14.89 Million |
| 2020 | -134.64% | -678.84% | 0.04x | 5.37x | $-55.83 Million |
| 2021 | -16.89% | -157.21% | 0.07x | 1.45x | $-92.71 Million |
| 2022 | -43.36% | -435.14% | 0.06x | 1.75x | $-133.12 Million |
| 2023 | -40.20% | -278.54% | 0.09x | 1.59x | $-127.05 Million |
| 2024 | -65.31% | -309.73% | 0.13x | 1.59x | $-150.25 Million |
| 2025 | -29.35% | -162.85% | 0.16x | 1.15x | $-136.21 Million |
Industry Comparison
This section compares Tango Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,677,567
- Average return on equity (ROE) among peers: -58.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tango Therapeutics Inc (TNGX) | $346.18 Million | -178.30% | 0.15x | $2.83 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About Tango Therapeutics Inc
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant … Read more